Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Proteolytic fragments of amyloid and post-translational modification of tau species in Cerebrospinal fluid (CSF) as well as cerebral amyloid deposition are important biomarkers for Alzheimer's Disease. We conducted genome-wide association study to identify genetic factors influencing CSF biomarker level, cerebral amyloid deposition, and disease progression. The genome-wide association study was performed via a meta-analysis of two non-overlapping discovery sample sets to identify genetic variants other than APOE ε4 predictive of the CSF biomarker level (Aβ1-42, t-Tau, p-Tau181P, t-Tau:Aβ1-42 ratio, and p-Tau181P:Aβ1-42 ratio) in patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. Loci passing a genome-wide significance threshold of P < 5 x 10-8 were followed-up for replication in an independent sample set. We also performed joint meta-analysis of both discovery sample sets together with the replication sample set. In the discovery phase, we identified variants in FRA10AC1 associated with CSF Aβ1-42 level passing the genome-wide significance threshold (directly genotyped SNV rs10509663 PFE = 1.1 x 10-9, imputed SNV rs116953792 PFE = 3.5 x 10-10), rs116953792 (Pone-sided = 0.04) achieved replication. This association became stronger in the joint meta-analysis (directly genotyped SNV rs10509663 PFE = 1.7 x 10-9, imputed SNV rs116953792 PFE = 7.6 x 10-11). Additionally, we identified locus 15q21 (imputed SNV rs1503351 PFE = 4.0 x 10-8) associated with CSF Aβ1-42 level. No other variants passed the genome-wide significance threshold for other CSF biomarkers in either the discovery sample sets or joint analysis. Gene set enrichment analyses suggested that targeted genes mediated by miR-33, miR-146, and miR-193 were enriched in various GWAS analyses. This finding is particularly important because CSF biomarkers confer disease susceptibility and may be predictive of the likelihood of disease progression in Alzheimer's Disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LocusZoom: regional visualization of genome-wide association scan results
Pruim, R. J., Welch, R. P., Sanna, S., Teslovich, T. M., Chines, P. S., Gliedt, T. P., Boehnke, M., Abecasis, G. R., & Willer, C. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq419 · Cited by 2,707 · cited 2×
“[38] Regional visualization of genome-wide association scan results was plotted using LocusZoom.”
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 2×
“03) for rs2588969 with LOAD.[20, 21] rs16934131 in KCNMA1 was significantly associated with age at onset (AAO) of LOAD (P = 0.”
BackgroundInfluentialTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 2×
“For example, we know that up to 36.1% of APOE ε4 allele non-carriers clinically diagnosed with Alzheimer’s Dementia do not have Alzheimer’s pathology as measured by PIB-PET.”
BackgroundInfluentialNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 2×
“03) for rs2588969 with LOAD.[20, 21] rs16934131 in KCNMA1 was significantly associated with age at onset (AAO) of LOAD (P = 0.”
BackgroundInfluentialFast and accurate genotype imputation in genome-wide association studies through pre-phasing
Howie, B., Fuchsberger, C., Stephens, M., Marchini, J., & Abecasis, G. R. (2012) · Nature Genetics · doi:10.1038/ng.2354 · Cited by 1,737
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 9×
“The primary goal of ADNI study has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessments can be combined to measure the progression of MCI and early AD.”
BackgroundInfluentialKathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386 · cited 1×
“APOE ε4 has been the most convincing genome wide signal in AD, and variants in APOE-APOC1-APOC4-APOC2 and TOMM40-APOE have previously been associated with total cholesterol, LDL cholesterol, and triglyceride concentrations.[29, 30] Cholesterol metabolism was implicated to be enriched in the etiology of AD in previous…”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Genotype Imputation with Thousands of Genomes
Howie, B., Marchini, J., & Stephens, M. (2011) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.111.001198 · Cited by 966
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Jones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606 · cited 1×
“[29, 30] Cholesterol metabolism was implicated to be enriched in the etiology of AD in previous study.[31] In the INRICH analysis, miR-33 targets are enriched in CSF GWAS analysis and miR-33 is critical in regulating cholesterol metabolism, affirming the interrelationship between cholesterol metabolism and AD process.”
BackgroundCandidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
Li, H., Wetten, S., Li, L., St. Jean, P. L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M. R., Briley, J. D., Borrie, M., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.3 · Cited by 499 · cited 1×
“org/ marker/HGVM16286779/results?t=2) inWDFY3 exhibited nominally significant interaction (SNP APOE ε4) in an AD case-control GWAS study.[27] GFRA1 gene, which encodes GDNF family receptor alpha 1, a member of the GDNF receptor family, is among the few genes with suggestive association to rate of cognitive decline in…”
BackgroundAutophagy in microglia degrades extracellular β-amyloid fibrils and regulates the NLRP3 inflammasome
Cho, M.-H., Cho, K., Kang, H.-J., Jeon, E.-Y., Kim, H.-S., Kwon, H.-J., Kim, H.-M., Kim, D.-H., & Yoon, S.-Y. (2014) · Autophagy · doi:10.4161/auto.29647 · Cited by 395 · cited 1×
“Among, the potential targets of miR-33, PRKAA1 (Protein kinase, AMP-activated, alpha 1 catalytic subunit) mediates an autophagic process to clear extracellular Aβ fibrils by microglia, the immune cells in the brain.[18] Other potential targets of miR-33 included ARID5B (AT rich interactive domain 5B (MRF1-like)), KCNM…”
BackgroundDissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383 · cited 1×
“[11] The largest CSF biomarker GWAS (N = 1,269) was based on a one stage analysis of four datasets leading to the identification of three novel genome-wide significant loci, an intronic imputed SNP in GLIS3 (associated with p-tau181p and t-tau), an intergenic imputed SNP between GMNC and OSTN (associate with t-tau), a…”
MethodTargeting the neural extracellular matrix in neurological disorders
Soleman, S., Filippov, M. A., Dityatev, A., & Fawcett, J. W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.050 · Cited by 244
INRICH: interval-based enrichment analysis for genome-wide association studies
Lee, P. H., O'Dushlaine, C., Thomas, B., & Purcell, S. M. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts191 · Cited by 238
Genome-wide association study of CSF biomarkers Aβ 1-42 , t-tau, and p-tau 181p in the ADNI cohort
Kim, S., Swaminathan, S., Shen, L., Risacher, S. L., Nho, K., Foroud, T., Shaw, L. M., Trojanowski, J. Q., Potkin, S. G., Huentelman, M. J., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318204a397 · Cited by 206
Cruchaga, C., Kauwe, J. S. K., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., Shah, A. R., Abraham, R., Hollingworth, P., Harold, D., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001101 · Cited by 128 · cited 1×
“identified a SNP located in intron 5 of the regulatory subunit of the PPP3R1 gene associated with CSF p-tau181 levels in two independent CSF sample sets.[11] The largest CSF biomarker GWAS (N = 1,269) was based on a one stage analysis of four datasets leading to the identification of three novel genome-wide significan…”
MethodPerineuronal nets protect against amyloid β-protein neurotoxicity in cultured cortical neurons
Miyata, S., Nishimura, Y., & Nakashima, T. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.066 · Cited by 101
Research works printed but not linked: 18
- 1998, Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiology of aging, 19, 109
- RA Frank, 2003, Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease, Neurobiology of aging, 24, 521
- MN Samtani, 2013, Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes, British journal of clinical pharmacology, 75, 146, 10.1111/j.1365-2125.2012.04308.x · DOI · Paper page
- C Andersson, 2008, Increasing CSF phospho-tau levels during cognitive decline and progression to dementia, Neurobiology of aging, 29, 1466, 10.1016/j.neurobiolaging.2007.03.027 · DOI
- VK Ramanan, 2014, APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study, Molecular psychiatry, 19, 351, 10.1038/mp.2013.19 · DOI · Paper page
- X Hu, 2011, Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment, Translational psychiatry, 1, e54, 10.1038/tp.2011.50 · DOI
- KJ Rayner, 2010, MiR-33 contributes to the regulation of cholesterol homeostasis, Science, 328, 1570, 10.1126/science.1189862 · DOI · Paper page
- N Rotllan, 2012, MicroRNA Regulation of Cholesterol Metabolism, Cholesterol, 2012, 847849, 10.1155/2012/847849 · DOI
- MM Carrasquillo, 2011, Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control study, Molecular neurodegeneration, 6, 54, 10.1186/1750-1326-6-54 · DOI · Paper page
- Y Kong, 2014, MicroRNA expression analysis of adult-onset Drosophila Alzheimer's disease model, Current Alzheimer research, 11, 882
- R Zhang, 2014, Screening of microRNAs associated with Alzheimer's disease using oxidative stress cell model and different strains of senescence accelerated mice, Journal of the neurological sciences, 338, 57, 10.1016/j.jns.2013.12.017 · DOI
- LL Wang, 2012, potential role of microRNA-146 in Alzheimer's disease: biomarker or therapeutic target?, The, 78, 398
- L Tan, 2013, Non-coding RNAs in Alzheimer's disease, Molecular neurobiology, 47, 382, 10.1007/s12035-012-8359-5 · DOI · Paper page
- YS Aulchenko, 2009, Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts, Nature genetics, 41, 47, 10.1038/ng.269 · DOI · Paper page
- J Marchini, 2010, Genotype imputation for genome-wide association studies, Nature reviews Genetics, 11, 499, 10.1038/nrg2796 · DOI · Paper page
- J Marchini, 2007, A new multipoint method for genome-wide association studies by imputation of genotypes, Nature genetics, 39, 906, 10.1038/ng2088 · DOI · Paper page
- BN Howie, 2009, A flexible and accurate genotype imputation method for the next generation of genome-wide association studies, PLoS genetics, 5, e1000529, 10.1371/journal.pgen.1000529 · DOI · Paper page
- S Purcell, 2007, PLINK: a tool set for whole-genome association and population-based linkage analyses, American journal of human genetics, 81, 559, 10.1086/519795 · DOI · Paper page
Cited by
Identification of common genetic risk variants for autism spectrum disorder
Autism Spectrum Disorder Working Group of the Psychiatric Genomics Consortium, Grove, J., BUPGEN, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, 23andMe Research Team, Ripke, S., Als, T. D., Mattheisen, M., Walters, R. K., Won, H., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0344-8 · Cited by 2,421
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 315
Self-citationGuerreiro, R., Ross, O. A., Kun-Rodrigues, C., Hernandez, D. G., Orme, T., Eicher, J. D., Shepherd, C. E., Parkkinen, L., Darwent, L., Heckman, M. G., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30400-3 · Cited by 270
(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetic Consortium (ADGC), Li, Z., Kapoor, M., Harari, O., Del-Aguila, J. L., Black, K., Carrell, D., Cai, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1685-y · Cited by 231
Common risk variants identified in autism spectrum disorder
Grove, J., Ripke, S., Als, T. D., Mattheisen, M., Walters, R., Won, H., Pallesen, J., Agerbo, E., Andreassen, O. A., Anney, R., et al. (2017) · doi:10.1101/224774 · Cited by 89
Metadata
- Authors
- Li, Q. S., Parrado, A. R., Samtani, M. N., Narayan, V. A., & Initiative, A. D. N.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-08-07
- Volume
- 10
- Issue
- 8
- Pages
- e0134000
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1926182559
- Cited by
- 40
- References
- 21
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.